Hector Vazquez Torres
General Practice · Ponce, PRNPI 1992305197
Payments from drug & device makers
Across 82 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$261
- AstraZeneca$218
- Johnson & Johnson$201
- Novo Nordisk$164
- Pfizer$157
- Lilly USA, LLC$137
- plus $461 from 11 others
What the payments were for
- Food & beverage$1,600100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 12 | $261 |
| AstraZeneca | 13 | $218 |
| Johnson & Johnson | 6 | $201 |
| Novo Nordisk | 9 | $164 |
| Pfizer | 9 | $157 |
| Lilly USA, LLC | 8 | $137 |
| Exact Sciences | 5 | $105 |
| GSK | 4 | $79 |
| Novartis | 4 | $62 |
| Boehringer Ingelheim | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Mylan Specialty L.p. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Merck | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$1,600 in reported general payments places this provider in the 90th percentile of 3,586 general practice providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 112 | $140,446 |
| EliquisApixaban | 76 | $90,772 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $86,954 |
| JanuviaSitagliptin Phosphate | 45 | $65,710 |
| TrulicityDulaglutide | 39 | $57,360 |
| FarxigaDapagliflozin Propanediol | 43 | $51,824 |
| OzempicSemaglutide | 38 | $43,442 |
| EntrestoSacubitril/Valsartan | 17 | $22,414 |
| VascepaIcosapent Ethyl | 24 | $17,301 |
| XareltoRivaroxaban | 13 | $14,568 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $9,237 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $9,120 |
| LantusInsulin Glargine,hum.Rec.Anlog | 38 | $7,635 |
| Atorvastatin Calcium | 658 | $5,576 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 139 | $5,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $51 | $140,446112 claims |
| PfizerEliquis | $157 | $90,77276 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $79 | $90,44087 claims |
| MerckJanuvia | $15 | $65,71045 claims |
| Lilly USA, LLCTrulicity | $137 | $57,36039 claims |
| AstraZenecaFarxiga | $218 | $51,82443 claims |
| Novo NordiskOzempic | $164 | $43,44238 claims |
| NovartisEntresto | $62 | $22,41417 claims |
| Johnson & JohnsonXarelto | $201 | $14,56813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in Ponce
- Jesus Rodriguez RodriguezPonce$4.9M
- Rafael Mendoza RodriguezPonce$592K
- Soria Diaz BaezPonce$192K
- Gregorio Cortes-MaisonetSan Juan$12.8M
- Barbara Orozco PerezCanovanas$5.1M
- Luis PaganDorado$3.3M
- Cindy MartinezHormigueros$3.2M
- Gustavo AlbizuMorovis$3.1M
- Elham GhorbaniDorado$1.2M
- Victor MorenoMaunabo$903K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.